Pramipeksol v ranikh i pozdnikh stadiyakh bolezni Parkinsona


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The basic approach in the treatment of patients with Parkinson's disease (PD) is the use of levodopa and dopamine receptor agonists (DRAs). Prolonged intake of levodopa is accompanied by the development of fluctuations in symptoms and drug-induced dyskinesias; so, in some cases of PD, especially in young patients, ADRs are considered as drugs of choice and can be used both alone and in combination therapy. One of the best representatives of the ADRs that have extensive evidence base is pramipexole (Mirapex). The article analyzes the multiform properties of pramipexole and its influence on motor and non-motor manifestations of PD; possible neuroprotective effects of the drug are discussed. The potential of a new form of pramipexole with controlled release and sustained 24-hour action (Mirapex PD) is considered.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Illarioshkin

Email: sni@neurology.ru. snillario@gmail.com

Әдебиет тізімі

  1. Левин О.С. Клиническая эпидемиология болезни Паркинсона // Болезнь Паркинсона и расстройства движений. Руководство для врачей по материалам II Национального конгресса. М., 2011. С. 5-9.
  2. Braak H, Tredici KD, Rueb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. NeurobiolAging 2003;24:197-211.
  3. Шток В.Н. и др. Экстрапирамидные расстройства. Руководство по диагностике и лечению. М., 2002.
  4. Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;7:229-38.
  5. Marsden CD Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81.
  6. Kebabian JW, Calne DB. Multiple receptor mechanism for dopamine. Nature 1979;227:93-96.
  7. Rodbell M. Signal transduction: evolution of an idea. In: Nobel Lectures, Physiology or Medicine 1991-1995 (ed. Ringertz N.). Singapore, 1997:220-36.
  8. Rascol O, Slaoui T, Regragui W, et al. Dopamine agonists. In: Handbook of Clinical Neurology, Vol. 84: Parkinson's disease and related disorders. Part II (eds. Koller WC, Melamed E). Edinburgh: Elsevier, 2007:73-92.
  9. Ogawa N, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor mediated antioxidant and neuroprotective effects of ropinirole. Parkinsonism Relat Disord 1999;5:1-81.
  10. Schapira AHV, Olanow CW. Neuroprotection in Parkinson's disease. Mysteries, Myths, and Misconceptions. JAMA 2003;291:358-64.
  11. Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000;42:287-91.
  12. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996;67:2208-11.
  13. Gu M, Iravani MM, Cooper JM. et al. Pramipexole protects against apoptotic cell death by nondopaminergic mechanisms. J Neurochem 2004;91:1075-81.
  14. Schapira AHV. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008;15(Suppl. 1):5-13.
  15. Stocchi F. Neuroprotection in Parkinson's disease: clinical trials. In: Handbook of Clinical Neurology, Vol. 84: Parkinson's disease and related disorders. Part II (eds. Koller WC, Melamed E.). Edinburgh, 2007:17-29.
  16. Parkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson's disease: design and methods of the CALM-PD study. J Clin Neuropharmacol 2000;23:34-44.
  17. Whone AL, Watts RL, Stoessl AJ et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
  18. LeWitte PA, Taylor DC. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 2008;5:210-25.
  19. Molho ES, Factor SA, Weiner WJ et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995;45:(Suppl.):225-30.
  20. Wong KS, Lu S-C, Shan D-E. et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003;216:81-7.
  21. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexol, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-28.
  22. Федорова Н.В. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона // Болезнь Паркинсона и расстройства движений. Руководство для врачей по материалам I Национального конгресса. М., 2008. С. 162-70.
  23. Иванова-Смоленская И.А., Маркова Е.Д., Иллариошкин С.Н. Агонисты дофаминовых рецепторов в лечении больных первичным паркинсонизмом молодого возраста // Неврол. журн. 2002. № 2. С. 38-41.
  24. Иллариошкин С.Н., Иванова-Смоленская И.А., Загоровская Т.Б. и др. Семилетний опыт применения Мирапекса у больных с различными формами первичного паркинсонизма // Журн. неврол. и психиатрии им. С.С.Корсакова 2006. № 11. С. 26-32.
  25. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-20.
  26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-68.
  27. Kunig G, Pogarell O, Moller JC, et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson s disease. Clin Neuropharmacol 1999;22:301-05.
  28. Moller JC, Oertel WH. Pramipexole in the treatment of advanced Parkinson s disease. Eur J Neurol 2000;7(Suppl. l):21-5.
  29. Reijinders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2007; 23:183-89.
  30. Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. Clin Neurosci 2001;13:187-196.
  31. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15 (Suppl. 1):14-20.
  32. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of deprtessive symptoms in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80.
  33. Zarate CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
  34. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of nondopaminergic treatments. J Neurol 2000;247 (Suppl. 2):II43-II50.
  35. Rascol O. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Eur J Neurol 2011;18 (Suppl. 1):3-10.
  36. Hauser RA, Schapira AH, Rascol O. et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010;25:2542-49.
  37. Schapira AH, Barone P, Hauser RA, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Movement Disorder Society 13th International Congress. 2009:199.
  38. Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord 2010;25:2326-32.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>